GT Biopharma Inc GTBP 深 沪
等待开盘 04-02 09:30:00 美东时间
0.4094
+0.001
+0.32%
华盛通- 最 高0.425
- 今 开0.41
- 成交量 59.37万股
- 最 低 0.40
- 昨 收 0.4081
- 总市值 1291.82万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 0.3915
- 委 比 95.24%
- 总股本 3155.39万
- 历史最高 591.99
- 量 比 1.07
- 振 幅 6.13%
- 历史最低 0.3915
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma, Inc. (NASDAQ: GTBP) announced that its Executive Chairman and CEO, Michael Breen, will participate in the 38th Annual Roth Conference on March 22-24, 2026, in Laguna Niguel, CA. The Company will present on March 24, 2026, at 1:30 PM PDT and will be available for one-on-one investor meetings. For more information, visit https://www.gtbiopharma.com. The Company focuses on immuno-oncology therapeutics using its proprietary TriKE® NK ce...
03-11 11:00
GT Biopharma reports FY results
GT Biopharma press release (GTBP): FY The Company reported a net loss of approximately $28.4 million for the year ended December 31, 2025, compared to $13.2 million for the prior year. The Company re...
03-03 03:42
GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent decrease over losses of $(1.66) per share from the same period last year.
03-02 22:28
GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026
Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalents of approximately $7 million as of December 31, 2025, and an unaudited proforma cash balance as of January 31, 2026 of
03-02 20:24
GTBP FY 2025 net loss widens to USD 28.4 million on non-cash fair value charge
GTBP FY 2025 net loss widens to USD 28.4 million on non-cash fair value charge GT Biopharma reported FY 2025 results, ending the year with cash and cash equivalents of about USD 7 million and citing an unaudited proforma cash balance of about USD 9 million as of Jan. 31, 2026, which it expects to fu
03-02 20:02
GT Biopharma to Present at Centurion One Capital Toronto Growth Conference
GT Biopharma to Present at Centurion One Capital Toronto Growth Conference GT Biopharma Inc. will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026, in Toronto, Ontario. The event will feature a presentation, panel discussion, and one-on-one i
02-17 20:30
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma CEO Michael Breen will attend the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026. The event will include presentations, panel discussions, and one-on-one investor meetings. GT Biopharma specializes in immuno-oncology therapies using its proprietary TriKE® NK cell engager platform, and holds an exclusive global license with the University of Minnesota for related therapies. For more information, please vis...
02-17 12:30
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq looked set for a firm open on Tuesday, stabilizing a
02-03 22:17
GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express B7-H3Unaudited proforma cash balance as of January 31, 2026 of approximately
02-03 21:33
GT Biopharma Receives FDA Clearance for IND Application of GTB-5550 TriKE
GT Biopharma Receives FDA Clearance for IND Application of GTB-5550 TriKE GT Biopharma Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors expressin
02-03 21:30
